Davis to become acting director of CDER after Hoeg exit, Bloomberg says

Tracy Beth Hoeg, who’d been serving as acting director of the FDA’s Center for Drug Evaluation and was a key ally of former FDA commissioner Marty Makary, is departing the agency in what is expected to be the first in a series of changes, people familiar with the matter told Bloomberg’s Rachel Cohrs Zhang. Michael Davis, currently the center’s deputy director, will become acting director, according to the report. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).